書籍詳細

未契約

書籍名	内科セミナーBLD4 出血・凝固異常
出版社	永井書店
発行日	1984-03-01
著者	織田敏次(編集) 阿部裕(編集) 中川昌一(編集) 滝島任(編集) 堀内淑彦(編集) 鎮目和夫(編集) 古川俊之(編集) 祖父江逸郎(編集) 内野治人(編集) 尾前照雄(編集)
ISBN
ページ数	383
版刷巻号
分野	臨床医学：内科血液
シリーズ	内科セミナー
閲覧制限	未契約

内科学の急速な進歩・発展は、細分化と専門化をもたらし、近年、ますますその度を深めております。それに伴い、臨床家に要求される知識の量は急増の一途をたどっており、質的にも知識のlife cycleはますます短縮し、日々新しい医学へと脱皮しているのが現状であります。このことは、専門外の知識・情報について疎遠になりがちなspecialistや、最新の情報を吸収しきれないgeneralistの増加という情況をうみ出しております。内科セミナーは、このような認識のもとに企画された内科治療全書であり、up to dateな知識・情報を、迅速に、かつ総合的に提供して、今日の要求に応えようとするものであります。

表紙
閲覧
執筆者一覧
閲覧
目次
閲覧
1. 凝固線溶系の理論
P.1閲覧
- §1 凝固因子と分析法
- §2. 血小板の微細構造と機能
- §3. 阻害因子
- §4. 血管壁との関係
2. 出血傾向とその対策
P.99閲覧
- §1. 血小板減少性紫斑病
- §2. 血小板機能異常症
- §3. 血友病と血友病類縁疾患
- §4. 線溶亢進
- §5. 薬剤による出血傾向
3. 凝固亢進の臨床
P.231閲覧
- §1. 播種性血管内凝固症候群(DIC)
- §2. 抗血栓療法
4. 各科領域の出血・凝固異常
P.291閲覧
- §1. 加齢と出血・凝固異常
- §2. 妊婦の出血傾向と凝固異常
- §3. 外科における出血傾向の問題
索引
P.353閲覧
奥付
閲覧

参考文献

1. 凝固線溶系の理論

P.40 掲載の参考文献

1) Macfarlane, R. G.:An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature, 202:498-499, 1964.
pubmed

2) 加藤久雄, 児玉謙次, 嶋田敏生, 大野安男, 諏合輝子:異種表面上でのウシ第XII因子の活性化機作-多糖硫酸およびサルファチドによる活性化と血小板成分による阻害. 臨床病理, 50:102-113, 1982.

3) Griffin, J. H.:Role of surface in surface-dependent activation of Hageman factor (blood coagulation Factor XII). Proc. Natl. Acad. Sci. USA, 75:1998-2002, 1978.
pubmed

4) Mandle, R. J., Colman, R. W. and Kaplan, A. P.:Identification of prekallikrein and high-molecular weight kininogen as a complex in human plasma. Proc. Natl. Acad. Sci. USA, 73:4179-4183, 1976.
pubmed

5) 嶋田敏生, 岩永貞昭:血液凝固系の開始反応機構. 臨床科学, 19:933-946, 1983.

6) Fujikawa, K. and Davie, E. W.:Human factor XII (Hageman Factor). Methods in Enzymology, pp. 198-210, Vol. 80, part C. Academic Press, New York, 1981.

7) Griffin, J. H. and Cochrane, C. G.:Recent advances in the understanding of contact activation reactions. Seminars in Thrombosis and Hemostasis, 5:254-273, 1979.
pubmed

8) 倉知幸徳, 藤川和雄:血液凝固反応の開始機構. 蛋白質, 核酸, 酵素, 25: 95-111, 1980.

9) Wuepper, K. D.:Prekallikrein deficiency in man. J. Exp. Med., 138:1345-1355, 1973.

10) Saito, H., Ratnoff, O. D., Waldmann, R. et al:Fitzgerald trait. Deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface-mediated reactions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhancing vascular permeability. J. Clin. Invest. 55:1082-1092, 1975.
pubmed

11) Ikari, N., Sugo, T., Fujii, S., Kato, H. and Iwanaga, S.:The role of bovine high-molecular weight (HMW) kininogen in contact-mediated activation of bovine Factor XII:Interaction of HMW kininogen with kaolin and plasma prekallikrein J. Biochem., 89:1699-1709, 1981.
pubmed

12) Waldmann, R., Scicli A. G., McGregor, R. K., Carretero, O. A., Abraham, J. P., Kato, H., Han, Y. N. Iwanaga, S.:Effect of bovine high molecular weight kininogen and its fragments on Fitzgerald trait plasma. Thromb. Res., 8:785-795, 1976.
pubmed

13) Oh-ishi, S., Katori, M., Han, Y. N. et al.:Possible physiological role of new peptide fragments related from bovine high molecular weight kininogen by plasma kallikrein. Biochm. Pharmacol., 26:115-120, 1977.

14) Stenflo, J., Fernlund, P., Egan, W. et al.:Vitamin K-dependent modification of glutamic acid residues in prothrombin. Proc. Natl. Acad. Sci. USA, 71:2730-2733, 1974.
pubmed

15) Stenflo, J. and Suttie, J. W.:Vitamin K-dependent formation of y-car-boxyglutamic acid. Ann. Rev. Biochem., 46:157-172, 1977.

16) Kisiel, W., Canfield, W. M., Ericsson, L. H. and Davie, E.W.:Anticoagulant properties of bovine plasma protein C, following activation by thrombin. Biochemistry, 16:5824-5831, 1977.
pubmed

17) Drakenberg, T., Fernlund, P., Roepstorff, P. and Stenflo, J.:B-Hydro-xyaspartic acid in vitamin K-dependent protein C, Proc. Natl Acad. Sci. USA, 80:1802-1806, 1983.

18) Katayama, K., Ericsson, L. H., Enfield, D. L et al.:Comparison of amino acid sequence of bovine coagulation factor IX (Christmas factor) with that of other vitamin K-dependent plasma proteins. Proc. Natl. Acad. Sci. USA, 76:4990-4994, 1979.
pubmed

19) DiScipio, R. G., Kurachi, K. and Davie, E.W.:Activation of human factor IX (Christmas factor). J. Clin. Invest. 61:1528-1538, 1978.

20) Enfield, D. L, Ericsson, K. H. Walsh, K.A. et al.:Bovine factor X1 (Stuart factor):Primary structure of the light chain. Proc. Natl Acad. Sci. USA, 72:16-19, 1975.

21) Titani. K., Fujikawa, Enfield, D. L et al.:Bovine factor X1 (Stuart factor):Amino-acid sequence of heavy chain. Proc. Natl. Acad. Sci. USA, 72:3082-3086, 1975.
pubmed

22) Subbaiah, P. V., Bajwa, S. S., Smith, C. M. and Hanahan, D. J.:Interactions of the components of the prothrombinase complex. Biochem. Biophys. Acta, 444:131-146, 1976.
pubmed

23) Vehar, G. A. and Davie, E. W.:Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry. 19:401-410, 1980.

24) Fay, P. J., Chavin, S. I., Schro der D., Yang, F. E. and Marder, V. J.:Purification and characterization of a highly purified human Factor VIII consisting of a single type of polypeptide chain. Proc. Natl. Acad. Sci. USA, 79:7200-7204, 1982.

25) Fujikawa, K., Coan, M. H., Legaz, M. E. and Davie, E. W.:The mechanism of activation of bovine factor X (Stuart Factor) by intrinsic and extrinsic pathways. Biochemistry, 13:5290-5299, 1974.
pubmed

26) Gommori, H. and Takeda, Y.:Properties of human tissue thromboplastins from brain, lung, arteries and placenta. Thromb. Haemostas, 36:90-103, 1976.

27) Bach, R., Nemerson, Y. and Konigsberg, W.:Purification and characterization of bovine tissue factor. J. Biol. Chem. 256:8324-8331, 1981.
pubmed

28) Broze, G. J. and Majerus, P. W.:Purification and properties of human coagulation factor VII. J. Biol Chem. 255:1242-1247, 1980.
pubmed

29) Kisiel, W., Fujikawa, K. and Davie, E. W.:Activation of bovine factor VII (Proconvertin) by factor XIIa (activated Hageman factor). Biochemistry, 16:4189-4194, 1977.
pubmed

30) Zur, M. and Nemerson, Y.:Kinetics of factor IX activation via the extrinsic pathway. J. Biol. Chem., 255:5703--5707, 1980.

31) Magnusson, S., Petersen, T. E., Sottrup-Jensen, L, Claeys, H.:Complete primary structure of prothrombin:Isolation, structure, and reactivity of ten carboxylated glutamic acid residues and regulation of prothrombin activation by thrombin. In:Proteases and Biological Control. Vol. II, pp. 123-149, Cold Spring Harbor, 1975.

32) Esmon, C. T., Owen, W. G. , Jackson C. M.:A plausible mechanism for prothrombin activation by Facter Xa, Factor Va, phospholipid and calcium ions. J. Biol. Chem., 249:8045-8047, 1974.

33) Nesheim, M. E., Myrmel, K. H., Hibbard, L and Mann, K. G.:Isolation and characterization of single chain bovine factor V. J. Biol. Chem., 254:508-517, 1979.
pubmed

34) Dahlback, B.:Human coagulation factor V. Purification and thrombin-catalyzed activation. J. Clin. Invest., 66:583-591, 1980.
pubmed

35) Suzuki, K., Dahlback, B., and Stenflo, J.:Thrombin-catalyzed activation of human coagulation Factor V. J. Biol. Chem., 257:6556-6564, 1982.
pubmed

36) Kane, W. H. and Majerus, P. W.:The interaction of human coagulation Factor Va with platelets, J. Biol. Chem. 257:3963-3969, 1982.
pubmed

37) Esmon, C. T. and Jackson, C. M.:The conversion of prothrombin to thrombin. III The factor Xa-catalyzed activation of prothrombin. J. Biol. Chem., 249:7782-7790, 1974.
pubmed

38) Morita, T., Iwanaga, S. and Suzuki, T.:The mechanism of activation of bovine prothrombin by an activator isolated from Echis carinatus venom and characterization of the new active intermediates. J. Bio-chem. 79:1089-1108, 1976.

39) Hemker, H. C., Bas, B. M. and Muller, A. D.:Activation of a proenzyme by a stoichiometric reaction with another protein the reaction between prothrombin and staphylocoagulase. Biochim. Biophys. Acta, 379:180-188, 1975.
pubmed

40) Doolittle, R. F.:Structure and function of fibrinogen. Horisons Biochem. Biophys, 3:164-191, 1977.
pubmed

41) Lottspech, F. and Henschen, A.:Amino acid sequence of human fibrin. Preimary note on the completion of the y-chain sequence. Hoppe-Seyler's Z. Physiol. Chem. 358:935-938, 1977.

42) Watt, K. W. K., Takagi, T. and Doolittle, R. F.:The amino acid sequence of the B-chain of human fibrinogen. Biochemistry, 18:68-76, 1979.

43) Doolittle, R. F.:Fibrinogen and fiibrin. Sci. Am., 245:1264-1273, 1981.

44) Schwartz, M. L, Pizzo, S. V., Hill, R. L. and McKee, P. A.:The subunit structures of human plasma and platelet factor XIII (fibrin stabilizing factor). J. Biol. Chem, 246:5851-5854, 1971.
pubmed

45) Chen, R. and Doolittle, R. F.:y-y crosslinking sites in human and bovine fibrin. Biochemistry, 10:4487-4491, 1971.

46) Lee, S. Y. and Chung, S. I.:Biosynthesis and degradation of plasma protransglutaminase (factor XIII). Fed. Proc., 35:1486, 1976.

47) Takagi, T. and Doolittle, R. F.:Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin. Biochemistry, 13:750-756, 1974.
pubmed

48) Cooke, R. D. and Holbrook, J. J.:The calcium induced dissociation of human plasma clotting factor XIII. Biochem. J. 141:79-84, 1974.
pubmed

49) McDonagh, R. P. et al.:Studies of the α-chain crosslinking of human fibrin. XV1th Internatl. Cong. Hematol., (Kyoto abstr.) 1976, pp. 311.

50) Mosher, D. F.:Cross-linking of cold-insoluble globulin by fibrin-stabilizing factor. J. Biol. Chem., 250:6614-6621, 1975.
pubmed

51) Nyman, D. and Duckert. F.:Factor XIII, fibrin and collagen. Thromb. Diath. Haemorrh., 34:551, 1975.
pubmed

52) Mosher, D. F.:Cross-linking of collagen and fibrin by Factor XIIIa. Localization of participating glutamyl residues to a tryptic fragment of fibronectin. J. Biol Chem. 255:1181-1188, 1980.

53) Mui, P. T. and Ganguly,:Cross-linking of actin and fibrin by fibrin stabilizing factor. Am. J. Physiol., 233:H346-349, 1977.
pubmed

54) Cohen, I., Bandala, L Y., Blankenberg, T. A., Siefring, G.E., JR. and Lorand, J. B.:Fibrinoligase-catalyzed cross-linking of myosin from platelet and skeletal muscle. Arch. Biochem. Biophys., 192:100-111, 1979.

55) Sakata, Y. and Aoki, N.:Cross-linking of α 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J. Clin. Invest. 65:290-297, 1980.

56) Wallen, P. and Wieman, B.:Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. Biochem. Biophys. Acta, 257:122-134, 1972.

57) Magnusson, S. et al.:Homologous"Kringle"structures common to plasminogen and prothrombin. Substrate speciffcity of enzymes activating prothrombin and plasminogen. In:Proteolysis and Physiological Regulation:Miami Winter Symposia (Robbins, D. W. and Brew, K. eds.) N. Y. Academic Press., 11:203-238, 1976.

58) Lerch, P. G., Rickli, E. E., Lergier, W. and Gillessen, D.:Localization of individual lysine-binding regions in human plasminogen and investigations on their complex-forming properties. Eur. J. Biochem., 107:7-13, 1980.
pubmed

59) Violand, B. M. and Castellino, F. J.:Mechanism of the urokinase-catalyzed activation of human plasminogen. J. Biol. Chem., 251:3906-3912, 1976.

60) Hijikata, A., Hirata, M. and Kitaguchi, H.:Effect of proteases on plasminogen activator release from isolated perfused dog leg. Thromb. Res., 20:521-531, 1980.
pubmed

61) Comp, P. C. and Esmon, C. T.:Generation of fibrinolytic activity by infusion of activated protein C into dogs. J. Clin. Invest., 68:1221-1228, 1981.

62) Binder, B. R., Spragg, J. and Austen, K. F.:Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates. J. Biol. Chem., 254:1998-2003, 1979.
pubmed

63) Hoylaerts, M., Rijken, D. C., Lijnen, H. R. and Collen, D.:Kinetics of the activation of plasminogen by human tissue plasminogen activator. J. Biol. Chem., 257:2912-2919, 1982.
pubmed

64) Gaffney, P. J.:Molecular aspects of fibrinolysis. Ann. N. Y. Acad. Sci., 370:551-567, 1981.
pubmed

65) 池松正次郎:FDP. 臨床病理, 特集27号, 229-248, 1976.

66) Lee-Own, V., Gordon, Y. B. and Chard, T.:The detection of neoantigenic sites on the D-dimer peptide isolated from plasmin digested crosslinked fibrin. Thromb. Res. 14:77-84, 1979.

67) 斎藤英彦:補体, 凝固, 線溶, キニン系の相互関係. 凝固・線溶・キニン (青木延雄, 岩永貞昭編) 中外医学社, pp. 435-443, 1979.

68) 加藤久雄, 岩永貞昭:キニン系酵素および蛋白質. I. 化学構造と機能. 凝固・線溶・キニン (青木延雄. 岩永貞昭編) 中外医学社, pp. 389-416, 1979.

69) Stenflo,:A new vitamin K-dependent protein. Purification from bovine plasma and preliminary chracterization. J. Biol. Chem., 251:355-363, 1976.

70) Kisiel, W.:Human plasma protein C. Isolation, characterization, and mechanism of activation bya-thrombin. J. Clin. Invest., 64:761-769, 1979.

71) Owen, W. G. and Esmon, C. T.:Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J. Biol. Chem., 256:5532-5535, 1981.
pubmed

72) Esmon, N. L., Owen, W. G. and Esmon, C. T.:Isolation of a membranebound cofactor for thrombin-catalyzed activation of protein C. J. Biol. Chem., 257:859-864, 1982.
pubmed

73) Suzuki. K., Stenflo, J., Dahlback, B. and Teodorsson, B.:Inactivation of human coagulation factor V by activated protein C. J. Biol. Chem., 258:1914-1920, 1983.
pubmed

74) Walker, F. J.:Regulation of activated protein C by protein S. The role of phospholipid in Factor V inactivation. J. Biol. Chem., 256:11128-11131, 1981.
pubmed

75) Griffin, J. H., Evatt, B., Zimmerman, T. S., Kleiss, A. and Wideman, T. S.:Deficiency of protein C in congenital thrombotic disease. J. Clin. Invest., 68:1370-1373, 1981.

76) Suzuki, K., Nishioka, J. and Hashimoto, S.:Protein C inhibitor. Purification from human plasma and characterization. J. Biol. Chem., 258:163-168, 1983.
pubmed

77) Suzuki, K., Nishioka, J., Kusumoto, H. and Hashimoto, S.:Mechanism of inhibition of activated protein C by protein C inhibitor. J. Biochem. 95:187-195, 1984.
pubmed

78) 片山幸一, 藤川和雄, 千谷晃一:ビタミンK依存性血液凝固因子. 蛋白質, 核酸, 酵素, 24:924-941, 1979.

79) 橋本仙一郎:血栓症の診断-血栓傾向の凝血学的診断. 臨床成人病, 8: 1639-1645, 1978.

80) 橋本仙一郎:止血機構検査成績の読み方. 臨床病理, 17:114-124, 1969.
Medical*Online

81) 橋本仙一郎:トロンボエラストグラム (第XIII因子を含む). medicina, 16:1752-1753, 1979.

82) Hashimoto, S. and Suzuki, K.:Von Willebrand Factor-Characterization of Interaction among von Willebrand Factor, Ristocetin and Platelet. ACTA HAEM. JAP. 42:851-863, 1979.

83) 橋本仙一郎:血液凝固スクリーニング法. Med. Tech. , 5:437-443, 1977.

84) Miale, J. B.:Laboratory Medicine Hematology, 4th ea., Saint Louis, C. V. Mosby, 1972, p. 1126-1127.

85) 橋本仙一郎:トロンビン時間法によるフィブリノーゲンの定量. 臨床病理, 21:615-620, 1973.
Medical*Online

86) 橋本仙一郎, 江川宏, 森良樹, 橋本良子:各種フィブリノーゲン測定法の比較検討. 臨床病理, 23:713-716, 1975.
Medical*Online

87) 橋本仙一郎:凝固検査用試剤の調整法. 臨床病理, 臨時増刊特集, 第27号: 68-84, 1976.

88) 橋本仙一郎:第VIII因子の測定とスクリーニング. 日本臨牀, 39:3728- 3736, 1981.

89) 鈴木宏治, 江川宏, 橋本仙一郎, 高橋健治:ニホンザルおよびアカゲザルの凝固線溶系に関する検討. 血液と脈管, 9:18-23, 1978.

90) 江川宏, 鈴木宏治, 松崎修, 石原明徳, 山際裕史, 橋本仙一郎:ニホンザルを用いた実験的 DIC に関する検討. 血液と脈管, 9:202-207, 1978.

91) 橋本仙一郎, 沢宏紀:尿中 FDP. 臨床病理, 31:480-488, 1983.
Medical*Online

92) 鈴木宏治, 西岡淳二, 橋本仙一郎:螢光性ペプチド基質を用いた尿中ウロキナーゼの測定. 臨床病理, 27:218-222, 1979.
Medical*Online

93) 橋本仙一郎, 鈴木宏治:MCA 法による血漿プレカリクレイン, 第X因子および尿中ウロキナーゼの測定. Biomed. J. 3:783-788, 1979.

94) 高松純樹, 岩永貞昭:フィブリノゲンの分子異常. 代謝, 17:1027-1043, 1980.

P.59 掲載の参考文献

1) 服部晃, 真田雅好, 飯泉俊雄, 伊藤粋子, 和泉徹, 松岡松三:血小板の外形と機能に関する研究, 第1報外形. 判定法と正常人の血小板外形. 血液と脈管, 8:588-597, 1977.

2) Hattori, A., Sanada, M., Kojima, T., Ihzumi, T. and Shibata, A.:Spherothrombocytosis in diseases and pregnancy. Lancet, 1:1027-1028, 1979.
pubmed

3) Behnke, O.:Electron microscopical observations on the surface coating of human blood platelets. J Ultrastr. Res., 24:51-69, 1968.

4) Skaer, R. T., Emmines, T. P. and Le, H., Skaer, B.:The fine structure of cell contacts in platelet aggregation. J. Ultrastructr. Res., 69:28-42, 1979.

5) Behnke, O.:An electron microscope study of the megakaryocyte of the rat bone marrow. 1. The development of the demarcation-mem-brane system and the platelet surface coat. J. Ultrastr. Res. 24:412-433, 1968.

6) Behnke, O. and Zelander, T.:Filamentous substructure of microtubules of the marginal bundle of mammalian blood platelets. J. Ultrastr. Res., 19:147-165, 1967.

7) White, J.G.:The substructure of human platelet microtubules, Blood, 32:638-648, 1968.
pubmed

8) White, J.G.:Effects of colchicine and vinca alkaloids on human platelets. II. Changes in the dense tubular system and formation of an unusual inclusion in incubated cells. Amer. J. Pathol., 53:447-461, 1968.

9) White, J.G.:The submembrane filaments of blood plateles. Amer. J. Pathol., 56:267-277, 1969.

10) Hattori, A., Koike, K., Ito, S. &Matsuoka, M.:Static and functional morphology of the pathological platelets in primary myelofibrosis and myeloproliferative syndrome. Ser. haematol. 8:126-150, 1975.
pubmed

11) 服部晃. 血小板の電子顕微鏡像. 血液と脈管. 1:667-703, 1970.

12) Behnke, O.:Electron microscopic observations on the membrane systems of the rat blood platelet. Anat. Rec. 158:121-138, 1967.
pubmed

13) 神前五郎:血小板の微細構造. 脂質と止血, 新宿書房, p. 10-22, 1975.

14) Hattori, A.:Some observations on the ultrastructure of blood platelets in normal and some clinical conditions, with special references to its abnormality. J. Electron Microscopy. 16:239-258, 1967.
pubmed

15) Ryo, R., Profitt, R. T. & Deuel, T. F.:Human platelet factor 4:Subcellular localization and characteristics of release from intact platelets. Thrombos. Res. 17:629-644, 1980.

16) 石原隆雄, 菅原譲:血小板の電顕的組織化学的研究 -Lysosomal enzy- me の Release reaction における意義について, 日血会誌, 37:93-106, 1974.

17) Pepper, D. S.:Macromolecules released from platelet storage organelles. Thrombos. Haemostas. 42:1667-1672, 1979.

18) White, J.G. Edson, J. R., Desnick, S. J., & Witkop, Jr. C. J.:Studies of platelets in a variant of the Hermansky-Pudlak syndrome. Amer. J. Pathol., 63:319-332, 1971.

19) Weiss, H. J. & Ames. R. P.:Ultrastructural findings in storage pool disease and aspirin-like defects of platelets. Amer. J. Pathol., 71:447-466, 1973.

20) Hattori, A., Jinbo, C., Ihzumi, T., Ito, S. and Matsuoka, M.:A scanning electron microscope study on hemostatic reaction. Early hemostatic plug formation and the effect of aspirin. Arch. Histol. Jap., 37:343-364, 1975.

21) Baumgartner, H. R., Stemerman. M. B., and Spaet, T. H.:Adhesion of blood platelets to subendothelial surface:distinct from adhesion to collagen. Experientia, 27:283-285, 1971.
pubmed

22) Hattori, A., Watanabe, T. and Izumi, T.:Scanning electron microscope study on hemostatic reaction. Mural thrombus after the removal of endothelium, with special references to platelet behavior, site of fibrin formation and microhemolysis. Arch. Histol. Jap., 41:205-227, 1978.

23) Hattori, A., Ito, S., Tsukada, T., Koike, K. & Matsuoka, M:Ultrastructure of platelet aggregation at an early stage. Thrombos. Diathes. haemorrh. (Suppl) 60:147-158, 1974.

24) White, J. G.:Electron microscopic studies of platelet secretion. In Progress in hemostasis and thrombosis. vol. 2. ed. by Spaet, T. H., Grune & Stratton, New York, p. 49-98, 1974.

25) 服部晃, 神保長三:血小板の粘着, 凝集, 放出反応と微細構造. 日血会誌, 39:633-652, 1976.

26) White, J. G., Krivit, W. and Vernier, R. L.:An ultrastructural investigation of fibrin clot utilizing ferritin labelled antihuman fibrinogen antibody. Blood, 24:443-450, 1964.

27) 服部晃, 小島知子, 高橋薫, 真田雅好, 飯泉俊雄, 長山礼三, 高橋芳右, 小林勲, 小池正, 柴田昭:DIC にみられた球状血小板症. 医学のあゆみ. 115:384-386, 1980.

28) 真田雅好, 服部晃, 飯泉俊雄, 伊藤粋子, 渡部透, 和泉徹, 桜川信男, 松岡松三, 黒滝栄子, 田中百合子, 織田島弘子, 関川秀子, 保坂安子: 血小板の外形と機能に関する研究 (第2報) -保存と振盤における血小板外形と粘着凝集能. 血液と脈管. 9:413-417, 1978.

29) 服部晃, 柴田昭:血小板自然凝集と循環凝集血小板. 医学のあゆみ. 111; 72～75, 1979.

30) 服部晃:血小板形態の異常. 日血全書, 丸善. 12; 33～55, 1980.

P.76 掲載の参考文献

1) Damus, P. S., Rosenberg, R. D.:Methods in Enzymology, Vol. 45, Proteolytic Enzymes, p. 653, Academic Press, New York, 1976.

2) Rosenberg, R. D., Damus, P. S.:J. Biol. Chem. 248, 6490, 1973.
pubmed

3) Highsmith, R. F., Rosenberg, R. D.:J. Biol. Chem. 249, 4335, 1974.
pubmed

4) Rosenberg, R. D.:Progress in Hemostasis and Thrombosis, Vol. 3 (ed. by Spaet, T. H.), p. 173, Grune & Stratton, New York, 1976.

5) Rosenberg, J. S., Mc Kenna, P., Rosenberg, R. D.:J. Biol. Chem. 250, 8883, 1975.
pubmed

6) Damus, P. S., Hicks, M, Rosenberg, R. D.:Nature (Lond.) 246, 355, 1973.
pubmed

7) Stead, N., Kaplan, A. P., Rosenberg, R, D.:J. Biol. Chem. 251, 6481, 1976.
pubmed

8) Godal, H. C., Rygh, M., Laake, K.:Thrombos. Res, 5, 773, 1974.

9) Wessler, S., Yin, E. T.:Thromb. Diath. Haemorrh. 32, 71, 1974.
pubmed

10) Yin, E. T., Wessler, S., Stoll, P. J.:J. Biol. Chem.. 246, 3703, 1971.
pubmed

11) Rosenberg, R. D., La Hiri, B., Talmo, R. G. et al:Fed. Proc. 33, 642, 1974.

12) Remold, H. G., Rosenberg, R. D.:J. Biol. Chem. 250, 6608, 1975.
pubmed

13) Egeberg, O.:Thromb. Diath. Haemorrh. 13, 516, 1965.
pubmed

14) Marciniak, E., Farley, C. H., Simone, P. A.:Blood 43, 219, 1974.

15) von Kaulla, E., von Kaulla, K N.:J. Med. 3, 349, 1972.
pubmed

16) van der Meer, J., Stoepman-van Dalen, E. A., Jansen, J. H. S.:J. Clin. Pathal. 26, 532, 1973.

17) Sas, G. et al:Thromb. Diath. Haemorrh. 32, 105, 1974.
pubmed

18) 青木延雄:代謝 10, 142, 1973.

19) Mann, L T. et al:Science 166, 517, 1969.
pubmed

20) Wessler, S., Yin, E. T.:Circulation 47, 671, 1973.
pubmed

21) 青木延雄, 吉田信彦, 山中桓夫:医学のあゆみ, 109, 970, 1979.

22) Harpel, P. C.:Methods in Enzymology, Vol 44, Proteolytic Enzymes (ed. by Lorand, L), p. 639, Academic Press, New York, 1976.

23) Steinbuch, M., Pejaudier, L, Quentin, M. et al:Biochim. Biophys. Acta 154, 228, 1968.
pubmed

24) Lebreton de Vonne, T., Mouray, H., Berthillier, G. et al:Biochim Biophys. Acta, 257, 365, 1972.
pubmed

25) Frenoy, J. P., Bourillon, R.:Biochim. Biophys. Acta 371, 168, 1974.

26) Harpel, P. C.:J. Exp. Med. 138, 508, 1973.
pubmed

27) Barrett, A. J., Starkey, P. M.:Biochem. J. 133, 709, 1973.
pubmed

28) Rinderknecht, H., Fleming, R. M., Geokas, M. C.:Biochim. Biophys. Acta 377, 158, 1975.
pubmed

29) Harpel, P. C., Mosesson, M. W.:J. Clin. Invest. 52, 2175, 1973.
pubmed

30) Rinderknecht, H., Geokas, M. C.:Biochim. Biophys, Acta 259, 233, 1973.

31) Mc Connell, D. J.:J. Clin. Invest. 51, 1611, 1972.
pubmed

32) Ganrot, P. O.:Ark. Kemi, 50, 577, 1967.

33) Abe, S., Nagai, Y.:J. Biochem. (Tokyo), 73, 897, 1973.
pubmed

34) Ohlsson, K.:Acta Physiol. Scand. 81, 269, 1971.
pubmed

35) Blatrix, C., Amouch, P., Prouet, J. et al:Pathol. Biol (Paris) 21, 11, 1973.

36) Bergqvist, D., Nilsson, I. M.:Thrombos. Haemostas. (abstract) 42, 219, 1979.

37) Moroi, M., Aoki, N.:J. Biol. Chem. 251, 5956, 1976.

38) Moroi, M., Aoki, N.:Biochim. Biophys. Acta 482, 412, 1977.
pubmed

39) Moroi, M., Aoki, N.:J. Biochem. (Tokyo) 82, 969, 1979.

40) Saito, H., Goldsmith, G. H., Moroi, M., Aoki N.:Proc. Natl. Acad. Sci. U.S.A. 76, 2013, 1979.
pubmed

41) Thorsen, S.:Biochim. Biophys. Acta 293, 55, 1975.

42) Aoki, N, Moroi, M., Tachiya, K.:Thrombos. Haemostas. 39, 22, 1978.

43) Sakata, Y., Tateno, K., Tamaki, T., Aoki, N.:Thromb. Res. 16, 279, 1979.
pubmed

44) Sakata, Y., Aoki, N.:J. Clin. Invest. 65, 290, 1980.

45) Aoki, N, Saito, H., Kamiya, T. et al:J. Clin. Invest. 63, 877, 1979.
pubmed

46) Aoki, N., Sakata, Y., Matsuda, M., Tateno, K.:Blood 55, 483, 1980.
pubmed

47) Thorsen, S., Glas-Greenwald, P., Astrup, T.:Thrombos. Diathes. Haemorrh. 28, 65, 1972.

48) Gurewich, V., Hyde, E., Lipinski, B.:Blood 46, 555, 1975.
pubmed

49) Aoki, N., Moroi, M., Matsuda, M., Tachiya, K.:J. Clin. Invest. 60, 361, 1977.
pubmed

50) Aoki, N.:Prog. Cardiovasc. Dis. 63, 877, 1979.

51) 江川宏, 鈴木宏治, 松崎修他:血液と脈管 9, 202, 1978.

52) Aoki, N.:Microembolism Syndrome (Saldeen T., ed.) P. 123. Almqvist & Wiksell International, Stockholm, 1979.

53) Aoki, N., Yamanaka, T.:Clim Chim. Acta 84, 99, 1978.

P.95 掲載の参考文献

1) Aasted, B.:Purification and characterization of human vascular plasminogen activator. Biochem. Biophys. Acta 621:241～254, 1980.

2) 青木延雄:血栓融解の阻害因子. 血栓症. 田中健蔵編, 76～82, 文光堂, 東京, 1977.

3) Aoki, N. and Kawano, T.:Inhibition of plasminogen activators by naturally occurring inhibitors in man. Amer. J. Physiol 223:1334～1337, 1972.

4) 有広英明:小児及び若年者の冠状動脈病変に関する組織化学的, 免疫組織化学的研究. 福岡医誌, 61:493～515, 1970.

5) Astrup, T.:Role of blood coagulation and fiibrinolysis in the pathogenesis of arteriosclerosis. In connective tissue, thrombosis and atherosclerosis. Ed., Page, I. H. P., 223～240, Academic Press, New York and London, 1959.

6) Astrup, T., Albrechtsen, O. K., Claassen, M. and Rasmussen, J.:Thromboplastic and fiibrinolytic activity of the hllman aorta. Circulation Res. 7:969～976, 1959.

7) Astrup, T. and Coccheri, S.:Thromboplastic and fibrinolytic activity of the arteriosclerotic human aorta. Nature 193:182～183, 1962.

8) Astrup, T.:Tissue activators of plasminogen. Fed. Proc. 25:42～51, 1966.

9) Baumgartner, H. R.:The subendothelial surface and thrombosis. Thromb. Diath. Haemorrh. Suppl. 59:91～105, 1974. 95

10) Coccheri, S. and Astrup, T.:Thromboplastic and fibrinolytic activities of large human vessels. Proc. Soc. Exp. Biol. Med. 108:369～372, 1961.

11) Curwen, K. D., Gimbrone, M. A. Jr., and Handin, R. I.:In vitro studies of thromboressistance. The role of prostacyclin (PGI2) in platelet adhesion to cultured normal and virally transformed human vascular endothelial cells. Lab. Invest. 42:366～374, 1980.

12) Donner, L.:Some coagulant properties of the arterial wall in atherosclerosis. J. Atheroscler. Res. 2:88～95, 1962.

13) Donner, L., Klener, P. and Roth, Z.:The plasminogen activator of the arterial wall. Thrombos. Haemostas. (Stuttg.) 37:436～443, 1977.

14) Hegt, V. N. and Brakman, P.:Histochemical study of an inhibitor of fibrinolysis in the human arterial wall. Nature 248:75～76, 1974.

15) Hegt, V. N. and Brakman, P.:Inhibition of fibrinolysis by the human vascular wall related to smooth muscles. Circulation 50:296, Suppl. III, 1974.

16) Hegt, V. N.:Localization and distribution of fibrinolysis inhibition in the wall of human arteries and veins. Thromb. Res. 10:121～133, 1977.

17) Hisano, S.:Immunofluorescence study on thrombolysis with special reference to the patterns of distribution and the contents of fibrin, plasminogen, α 2-macroglobulin and urokinase in artificial thrombi, Thrombos. Haemostas. 39 (1):53～60, 1978.

18) 伊藤琢夫:動脈壁の Thromboplastic activity の研究, 特に動脈硬化症と本活性の関連に関する検討. 日内会誌, 53:972～988, 1964.

19) 風間睦美:血栓形成における凝固因子の意義(2)第XIII因子, 血栓症. 田中健蔵編. 34～40, 文光堂, 東京, 1977.

20) Kinjo, M., Oka, K., Naito, S., Kohga, S., Tanaka, K., Oboshi, S., Hayata, Y. and Yasumoto, K.:Thromboplastic and fibrinolytic activities of cultured human cancer cell lines. Br. J. Cancer 39:15～23, 1979.

21) Kirk, J. E.:Thromboplastin activities of human arterial and venous tissue. Proc. Soc. Exp. Biol. Med. 109:890～892, 1962.

22) Kodama, Y. and Tanaka, K.:Thromboplastic and fibrinolytic activities of V2 and V7 carcinomas of rabbit, with special reference to fibrin deposition and thrombus formation in the tumors. Acta Path. Jap. 28:279～286, 1978.

23) 古賀通義:家兎肺動脈における血栓の融解器質化に関する実験的研究. 福岡医誌, 62:525～540, 1971.

24) 甲賀新:プラスミノゲンアクチベータの測定法とその意義. 臨床病理, 22:552～558, 1974.

25) Kwaan, H. C. and Astrup, T.:Fibrinolytic activity in thrombosed vein. Circul. Res. 17:477～483, 1965.

26) Loskutoff, D. J. and Edgington, T. S.:Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc. Natl. Acad, Sci. U. S. A. 74:3903～3907, 1977.

27) Murray, M.:Vasculokinase, a clotting substance from arteries. Am. J. Clin. Path. 36:500～504, 1961.

28) Murray, M. and Johnson, R.:Distribution of vasculokinase in human blood vessels. Thromb. Diath. Haemorrh. 8:96～100, 1962.

29) Mustard, J. F., Kinlough-Rathbone, R. L. and Packham, M. A.:Recent status of research in the pathogenesis of thrombosis. Thromb. Diath. Haemorrh., Suppl. 59:157～188, 1974.

30) Nilsson, I. M.:Local fibrinolysis as a mechanism for haemorrhage. Thromb. Diathes. Haemorrh. 34:623～633, 1975.

31) O'Brien, J. R.:Some properties of damaged endothelial cells. Nature 184:1580～1581, 1959.

32) Ohta, G.:Morphology of the vascular endothelium. An investigation of the morphogenesis of incipient thrombosis. Acta Path. Jap. 10 (Suppl.):377～394, 1960.

33) Oka, K. and Tanaka, K.:Intravascular coagulation in autopsy cases with liver diseases. Thromb. Haemostas. 42 (2):564～570, 1979.

34) Oka, K., Tanaka, K.:Local fibrinolysis of Fsophagus and stomach as acause of hemorrhage in liver cirrhosis. Thromb. Res. 14 (6):837～844, 1979.

35) Onoyama, K. and Tanaka, K.:Fibrinolytic activity of the arterial wall Thromb. Diath. Haemorrh. (Stuttg) 21:1～11, 1969.

36) 大石正晃:動脈壁の凝固線溶能に関する研究. 第1編 Vasculokinase 様物質について. 日内会誌より引用.

37) Pepper, D. S. and Allen, R.:Isolation and characterization of human cadaver vascular endothelial activator. Progress in Chemical Fibrinolysis and Thrombolysis 3:91～110, 1978.

38) 佐渡島省三:脳動脈粥状硬化の発生進展に関する組織化学的・免疫組織化学的研究. 福岡医誌, 68:45～67, 1977.

39) Stevenson, T. D., Schrodt, G. R. and Reed, L. M.:The coagulant properties of normal and atherosclerotic aortas. Am. J. Med. Sci. 241:632～636, 1961.

40) 住吉昭信:大動脈, 冠状動脈ならびにその他の動脈壁におけるフィブリン (フィブリノーゲン) の存在と動脈硬化との関連性について. 福岡医誌, 59:542～557, 1968.

41) Sumiyoshi, A., Tanaka, K.:Endothelial damage and thrombosis:a scanning and transmission electron microscopic study. Thromb. Res. 8 Suppl. II:277～285, 1976.

42) 住吉昭信:血栓形成における内皮細胞障害の意義. 血栓症. 田中健蔵編, 15～20, 文光堂, 東京, 1977.

43) 鈴木友二:血栓融解における線溶系活性化機構. ibid. 68～75.

44) 田中健蔵:血栓症. 福岡医誌, 59:337～361, 1968.

45) Tanaka, K.:Thrombus and coagulation factors in the genesis of arteriosclerosis. Acta. Path. Jap. 18:91～106, 1968.

46) 田中健蔵, 岩田康:血管壁の組織線溶活性 -その血栓溶解並びに動脈硬化の発生進展における意義- 脈管学, 10:227～235, 1970.

47) 田中健蔵:線溶系と動脈硬化. 臨床と研究, 48:528～533, 1971.
Medical*Online

48) Tanaka, K., Kohga, S., Kinjo, M. and Kodama, Y.:Tumor metastasis and thrombosis, with special reference to thromboplastic and fibrinoytic activities of tumor cells. In Gann Monograph on Cancer Research No. 20; Cancer Metastasis. Ed., Stansly, P. G. and Sato, H. pp. 97～119, Uhiversity of Tokyo Press, Tokyo. 1977.

49) 田中健蔵:線溶現象の病理的意義. 日病会誌, 66:3～26, 1977.

50) 田中健蔵:血栓症の病理. 血栓症. 田中健蔵編, 1～14, 文光堂, 東京, 1977.

51) 田中健蔵:血栓融解の機序-総論. ibid. 59～67.

52) 田中健蔵:線溶の病理組織学. 日本血液学全書 12. 出血性素因・臨床. 387～404.

53) Todd, A. S.:Endothelial fibrinolysis and blood flow. Lancet 1:1179, 1971.
pubmed

54) Todd, A. S.:Endothelium and fibrinolysis. Atherosclerosis 15:137～140, 1973.

55) Ubatuba, F. B., Moncada, S. and Vane, R.:The effect of prostacyclin (PGI) on platelet behaviour. Thrombus formation in vivo and bleeding time. Thromb. Haemostas. (Stuttg.) 41:425～435, 1979.

56) Warren, B. A. and Khan, S.:The ultrastructure of the lysis of fibrin by endothelium in vitro. Br. J. Exp. Path. 55:138～148, 1974.

57) 渡辺照男:血管壁の凝固線溶活性に関する研究. 福岡医誌, 61:682～694, 1970.

58) Watanabe, T. and Tanaka, K.:The role of coagulation and fibrinolysis in the development of rabbit Masugi nephritis. Acta Path. Jap. 26:147～165, 1976.

2. 出血傾向とその対策

P.147 掲載の参考文献

1) Wakisaka, G.:Idiopathic thrombocytopenic purpura as observed from the viewpoint of autoimmune desease. Acta Haematol. Jap. 25:341 (1962).

2) Wakisaka, G:Studies on platelet antibodies in idiopathic thrombocytopenic purpura and experimental thrombocytopenias. Acta Haematol. Jap. 27:663 (1964).

3) 安永幸二郎:特発性血小板減少性紫斑病. 臨床血液 13:504 (1972).

4) Harker, L. A.:Thrombokinetics in idiopathic thrombocytopenic purpura. Br. J. Haematol. 19:95 (1970).

5) Wintrobe, M. M.:Kinetics of thrombopoiesis. "Clinical Hematology" p. 383, Lea & Febriger, Philadel. (1974).

6) 清水弘之, 青木国雄, 加藤孝之, 野見山一生:特発性血小板減少性紫斑病の全国患者推計. 日本公衆衛生雑誌 25:341 (1978).147

7) 安永幸二郎:慢性ITP患者の治療に関する統計的観察, 厚生省特定疾患特発性造血障害調査研究班昭和53年度研究業績報告書, 532 (1979).

8) van Boxtel, C. J., F. Qosterhof and C. P. Engelfriet.:Immunofluorescence microphotometry for the detection of platelet antibodies-III. Demonstrtion of autoantibodies against platelets. Scand. J. Immunol. 4:657 (1975).

9) Dixon, R., W. Rosse and L. Ebert:Quantitative determination of antibody in idiopathic thrombocytopenic purpura:Correlation of serum and platelet-bound antibody in clinical response. N. Engl. J. Med. 292:230 (1975).

10) 安永幸二郎, 内野治人:慢性 ITP の治療の実態と治療方式の検討, とくに摘脾後免疫抑制療法の意義について. 厚生省特定疾患特発性造血障害調査研究班, 昭和52年度研究業績報告書 414 (1977).

11) 安永幸二郎:ITP の治療, 血液疫患最近の進歩 (高久史磨編) 金原出版, 333 (1978).

12) 島田逸人, 村田匡好, 麻生武志, 西村敏雄, 安永幸二郎:ITP 合併妊娠における副腎皮質ステロイド投与の影響, ことに新生児に対する効果について. 産科婦人科 44:1279 (1977).

13) Najean, Y. and N. Ardaillon:The sequestration site of platelets in idiopathic thrombocytopenic purpura; Its correlation with the results of splenectomy. Br. J. Haematol. 21:153 (1971).

14) Finch, S. C., O. Castro, M. Covey, R. Erichson and P. McPhedran:Immosuppressive therapy of chronic idiopathic thrombocytopenic purpura. Am. J. Med. 56:4 (1974).

15) Ahn, Y. S., W. J. Harrington, R. C. Seelman and C. S. Eytel:Vincristine therapy of idiopathic anc secondary thrombocytopenias. N. Engl. J. Med. 291:376 (1974).

16) Lacey, J. V. and J. A. Penner:Management of idiopathic thrombocytopenic purpura. Sem. Thromb. Hemost. 3:160 (1977).

17) Amorosi., E. L. and J. E. Ultmann:Thrombotic thrombocytopenicpurpura, report of 16 cases and review of the literature. Medicine 45:139 (1966).

18) Brain, M. C.:Hemolytic-uraemic syndrome. Lancet ii, 1394 (1968).

19) Stuart, M. J.:Inherited defects of platelet function. Sem. Hematol. 12:233 (1975).

20) Hardisty, R. M.:Disorders of platelet function. Br. Med. Bull. 33:207 (1977).
pubmed

21) Lusher, J. M. and Barnhart, M. I.:Congenital disorders affectingplatelets. Sem. Thromb. Hemost. 4:123 (1977). 147

22) Yasunaga, K.:Classification of hereditary platelet function disordersand diagnostic criteria:Inductive study based on a nationwide survey. Acta. Haematiol. Jap. 41:946 (1978).

23) Glanzmann, E.:Hereditare hemorrhagische Thrombasthenie. Ann. Paediatr. 88:113 (1918).

24) Inceman, S., A. Unugur and M. Aran:Essential athrombia. Thromb. Diath. Haemorrh. 8:502 (1962).

25) Bernard, J and P. Soulier:Sur une novelle variete de dystrophiethrombocytaire hemorragipare congenitale. Sem. Hop. Paris 24:3217 (1948).

26) Holmsen, H. and H. J. Weiss:Further evidence for a deficient storagepool of adenine nucleotides on platelets from some patients withthrombocytopathia-"storage pool disease". Blood 39:197 (1972).

27) Hardisty, R. M., D.C.B. Mills and K. Ketsaard:The platelet defect associated with albinism. Br. J. Haematol. 23:677 (1972).

28) Hirsh, J., D. J. Castelan and P. B. Loder:Spontaneous bruisising assocaited with defect in interaction of platelets with connective tissue. Lancet ii:18 (1967).

29) Horowitx, H. I.:Uremic toxins and platelet tunction. Arch. Intern. Med. 126:823 (1970).

30) 安永幸二郎:抗血小板剤. 臨床と研究 54:3152 (1979).

P.192 掲載の参考文献

1) 吉田邦男:小児血液疾患の臨床的研究, 昭和51年度小児慢性疾患に関する臨床的研究報告書, 厚生省心身障害研究小児慢性疾患研究班, 1976.

2) 福井弘:凝固第1相の阻止物質, 日血会誌 36:457, 1973.

3) 奥田忠美:血友病A及びvon Willebrand 病の免疫・凝血学的研究第1報, 奈医誌, 29:22, 1978.

4) Zimmerman, T. S., Ratnoff, O. D. and Powell, A. E.:Immunologic differentiation of classic hemophilia (factor VIIIdeficiency) and von Willebrand's disease. With observation on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on acquired circulating anticoagulant against antihemophilic factor. J Clin. Invest. 50:244, 1971.

5) Peake, I. R., Bloom. A. L., Giddings, J. C. and Ludlam, C. A.:An immunoradiometric assay for procoagulant factor VIII antigen:Results in hemophilia, von Willebrand's disease and fetal plasma and serum Brit. J. Haemat. 42:269, 1979.
pubmed

6) Zimmerman, T. S., Ratnoff, O. D. and Littell, A. S.:Detection of carriers of classic hemophilia using an immunologic assays for anti-hemophilic factor (Factor VIII). J. Clin. Invest. 50:255, 1971.

7) 吉岡章, 福井弘:第VIII,IX因子定量法, Medical Technology. 5:463, 1977.

8) 福井弘:第VIII因子および第IX因子製剤による血友病の補充療法. Medical Postgraduates. 17:569, 1979.

9) Mannucci, P. M., Ruggeri, Z. M., Pareti, F. I. and Capitanio, A.:1-Deamino-8-D-arginine vasopressin:A new pharmacological approach to the management of haemophilia and von Willebrand's disease. Lancet, i. 869, 1977.

10) Yoshioka, A., Takase, T., Fujimura, Y., and Fukui, H.:Large dose infusion of factor VIII concentrates in hemophilia A. Proceedings of the 1st International Symposium on Hemophilia Treatment, Tokyo, 31, 1979.

11) 吉岡章, 福井弘:血液凝固と免疫, 2. 血友病Aと von Willebrand 病. Immunohaematology. 2:194, 1980.

12) 藤村吉博, 嶋緑倫, 三村良明, 松山郁子, 三上定昭, 吉岡章, 福井弘:第VIII 因子抑制物質測定法に関する検討. Immunohaematology 2:252, 1980.

13) 長尾大:血友病患児における血液製剤投与と Au 抗原および肝炎との関連性, 日輸会誌. 20:201, 1974.

14) 吉岡章:VII血友病患者の療育. D. 遺伝相談, 結婚・家族計画. 血友病 (福武勝博, 藤巻道男, 長尾房大編集) 全国ヘモフィリア友の会 P. 531. 名古屋, 1981.

15) Rabiner, S. F. and Telfer, M. C.:Home transfusion for patients with hemophilia A. New Engl. J. Med. 283:1011, 1970.
pubmed

16) Discipio, R. G., Hermodson, M. A., Yates, S. G. and Davie, E. W.:A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor) and protein S. Biochemistry. 16:698, 1977.

17) Osterud, B. and Flengsrud, R.:Purification and some characteristics of coagulation factor IX from human plasma. Biochem. J., 145:469, 1975.
pubmed

18) Roberts, H. R., Grizzle, J. E., McLester, W. D. and Penick, G. O.:Genetic variants of hemophilia B:detection by means of a specific PTC inhibitor. J. Clin. Invest. 47:360, 1968.

19) Hougie, C. and Twomey, J. J.:Haemophilia BM:a new type of factor IX deficiency. Lancet i:698, 1967.
pubmed

20) Denson, K. W. E., Biggs, R. and Mannucci, P. M.:An investigation of three patients with Christmas disease due to an abnormal type of factor IX. J. Clin. Pathol. 21:160, 1968.

21) Orstavik, K. H., Osterud, B., Prydz. H. and Bery, K.:Electroimmunoassay of factor IX in hemophilia B. Thromb. Res. 7:373, 1975.

22) Kasper, C. K., Osterud, B, Minami, J. Y. Shonick, W. and Rapaport, S. I.:Hemophilia B:Characterization of genetic variants and detection of carriers. Blood. 50:351, 1977.
pubmed

23) Rabe, F. and Salomon:Uber Faserstoffmangel im Blute bei einem Falle von Hamophilie. Deutsch. Arch, Klin. Med., 132:240, 1920.

24) de Vries, A., Rosenberg, T., Kochwa, S. and Boss, J. H:Precipitating antifibrinogen antibody appearing after fibrinogen infusions in a patients with congenital afibrinogenemia. Am. J. Med., 30:486, 1961.

25) Mammen, E. F., Prasad, A. S., Barnhart, M. I. and Au. C. C.:Congenital dysfibrinogenemia:Fibrinogen Detroit. J. Clin. Invest. 48:235, 1969.
pubmed

26) Imperato, C. D., and Dettori, A. G.:Ipofibrinogenemia congenita con fibrinoastenia. Helv. Paediatr. Acta, 13:380, 1958.

27) Blomback, M., Blomback, B., Mammen, E. F.:Fibrinogen Detroit:A molecular defect in the N-terminal disulfide knot of human fibrinogen? Nature, 218:134, 1968.

28) Shapiro, S. S. and McCord. S.:Prothrombin, Progress in hemostasis and thrombosis. vol 4. ed. Spaet, TH. Grune & Stratton p. 177. New York, San Francisco, London, 1978.

29) Owren, P. A.:Parahaemophilia. Haemorrhagic diathesis due to abscence of a previously unknown cloting factor. Lancet, 1, 446, 1947.

30) 吉岡章, 藤村吉博, 北脇達雄, 吉岡慶一郎, 隅田秀文, 川原浩二:先天性第 V因子欠乏症 (Parahemophilia) の1例. 自験例と本邦報告例の文献的考察, 臨床血液. 16:953, 1975.

31) Alexander, B., Goldstein, R., Landwehr, G. and Cook, C. D.:Congenital SPCA defficiency:A hitherto unrecognized coagulation defect with hemorrhages rectified by serum and serum fractions. J. Clin. Invest. 30:596, 1951.

32) Goodnight, S. H., Feinstein, D. I., Osterud, B. and Rapaport, S. I.:Factor VII antibody-neutralizing material in hereditary and acquired factor VII deficiency. Blood. 38:1, 1971.
pubmed

33) Telfer, T. P., Denson, K. W. E. and Wright, D. R.:A, 'new' coagulation defect. Brit. J. Haemat., 2:308, 1956. 192

34) Hougie, C., Barrow, E. M. and Graham, J. B.:Stuart Clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called 'stable factor' (SPCA. proconvertin, factor VII) deficiency. J. Clin. Invest. 36:485, 1957.

35) Girolami, A., Molaro, G., Lazzarin, M., Scarpa, R. and Brunetti, A.:A 'new' congenital haemorrhagic condition due to the presence of an abnormal factor X (Factor X Friuli):Study of a large kindred. Brit. J. Haemat. 19:179, 1970. 192

36) Rosenthal, R. L, Dreskin, O. H. and Rosenthal, N:New hemophilia-like disease caused by deficiency of a third thromboplastin factor. Proc. Soc. Exp. Biol. Med. 82:171, 1953.
pubmed

37) Saito, H. and Goldsmith, G. H.:Plasma thromboplastin antecedent (PTA, factor XI):A specific and sensitive radioimmunoassay. Blood. 50:377, 1977.
pubmed

38) Duckert, F., Jung, E. and Shmerling, D. H.:Hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb. Diath. haemorrh. 5:179, 1960.
pubmed

39) 福井弘, 三上貞昭, 奥田忠美, 村嶋徳昭, 山本徹也, 徳田晴厚:先天性第VIII 因子欠乏症に対する第XIII因子濃縮剤の輸注効果, 基礎と臨床. 8:3203, 1974.

40) von Willebrand, E. A.:Hereditare Pseudohemofili. Finska Lak. Sallsk. Handl. 68:87, 1926.

41) Nilsson, I. M., Blomback, M., Jorpes, E., Blomback, B. and Johansson, S. A.:von Willebrand's disease and its correction with human plasma fraction I-O. Acta Med. Scand., 159:179, 1957.
pubmed

42) 福井弘, 馬島保, 田川徳治:出血時間延長を伴う AHF 欠乏症の女児2症例. 日血会誌. 21:608, 1958.

43) Howard, M. A. and Firkin, B. G.:Ristocetin-a new tool in the investigation of platelet aggregation. Thromb. Diath. haemorrh., 26:362, 1971.
pubmed

44) Fukui, H., Yoshioka, A., Mikami, S., Takase. T., Fujimura, Y., Takahashi, Y., Nishino, M. and Iwagaki, K.:Pathophysiology of von Wille. brand's disease:Qualitative and quantitative analysis of von Willebrand protein. Acta Haem. Jap. 41:839, 1979.

45) Ruggeri, Z. M., Mannucci, P. M., Jeffcoate, S. L and Ingram, G. I. C.:Immunoradiometric assay of factor VIII related antigen, with observations in 32 patients with von Willebrand's disease. Brit. J. Haemat. 33:221, 1976.

46) 福井弘:von Willebrand's disease. 臨床血液. 18:575, 1977.

47) 西野正人:ヒト第VIII因子高分子量分画の不均一性に関する研究. 第3報. 血友病A及び von Willebrand 病クリオプレチピテート及びクリオ上清第VIII因子関連抗原のポリアクリルアミドアガロースゲル・二次元交叉免疫電気泳動像. 奈医誌. 31:15, 1980.

48) Sultan, T., Simeon, J., Maisonneuve, P. and Caen, J. P.:Immunologic studies in von Willebrand, s disease. Alteration of factor VIII/von Willebrand protein after transfusion with plasma concentrates in patients with von Willebrand's disease. Thromb. Haemost., 35:110, 1976.

49) Mannucci, P. M., Meyer, D., Ruggeri, Z. M., Koutts, J. Ciavarella, N. and Lavergne, J. M.:Precipitating antibodies in von Willebrand's disease. Nature, 262:141, 1976.
pubmed

50) 福井弘, 奥田忠美, 高瀬俊夫, 三上貞昭, 吉岡章, 藤村吉博, 吉岡慶一郎: von Willebrand 因子抑制作用を示した von Willebrand 病亜型の2症例. 日血誌. 41:897, 1978.

P.209 掲載の参考文献

1) Collen, D., Ong, E. B. & A. J. Johnson:Human plasminogen:in vitro and in vivo evidence for the biological integrity of NH2-terminal glutamic acid plasminogen. Thromb. Res., 7:515-529, 1975.

2) Moroi, M. & N. Aoki:Isolation and characterization of α 2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J. Biol. Chem., 251:5956～5965, 1976.

3) Mullertz, S. & I. Clemmesson:The primary inhibitor of plasmin in human plasma. Biochem. J., 159:545～553, 1976. 209

4) Collen, D.:Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur. J. Biochem., 69:209～216, 1976.

5) Abiko, Y. et al:Plasminogen-Plasmin System-V. A stoichiometric equilibrium complex of plasminogen and a synthetic inhibitor. Bio-chim. Biophys. Acta, 185:424～431, 1969.

6) Iwamoto, M.:Plasminogen-Plasmin System-IX. Specific binding of tranexamic acid to plasmin. Thrombos. Diathes. Haemorrh., 33:573～585, 1975.

7) Aoki, N. et al:Congenital deficiency of α 2-Plasmin inhibitor associated with severe hemorrhagic tendency. J. Clin. Invest., 63:877～884, 1979.

8) 神谷忠他:先天性 α2PI 欠損症と抗プラスミン療法. 第19回プラスミン研究会報告集, 58～62, 1979.

9) 今岡真義:外科領域における癌と DIC. 癌と化学療法, 6 (6), 1229～ 1236, 1979.

10) 今岡真義他:DICの治療; 最近の進歩外科の症例を中心に救急医学, 3 (5), 513～518, 1979.

11) Aoki, N. & T. Yamanaka:α 2-Plasmin inhibitor levels in liver diseases. Clin. Chim. Acta, 84:99～105, 1978.

12) Kakkar, V. V. et al:Deep vein thrombosis of the leg.-Is there a "High Risk" group?-Am. J. Surg., 120:527～530, 1970.

13) 神前五郎他:手術と出血傾向. 内科シリーズ, No. 27 (VIII), 344～354, 南江堂, 1977.

14) Imaoka, S.:DIC associated with Surgical Diseaes. Acta Haemat. Jap., 41 (6):68～72, 1978.

15) 今岡真義他:急性閉塞性化膿性胆管炎の外科的治療-とくにDICとの関連において-日本消化器外科学会雑誌, 11 (1):100～107, 1978.

P.228 掲載の参考文献

1) De Gruchy, G. C.:Drug-induced blood disorders. Blackwell, Oxford, 1975.

2) Bottiger, L. E., Furhoff, A. K., and Holmberg, L.:Drug-induced blood dyscrasias. A ten-year material from the Swedish Adverse Drug Reaction Committee. Acta Med. Scand. 205:457～461, 1979.

3) Ackroyd, J. F.:Thromboytopenic purpura due to drug hypersensitivity. Clinical course, diagnosis and pathogenesis in Sensitivity Reactions to Drugs (ed, Rosenheim, M. L. and Moulton, R.) p. 28～62, Blackwell, Oxford, 1958.

4) 大久保滉:日本における薬物の血液障害, 臨床血液 15:230～236, 1974.

5) Bottiger, LE. and Westerholm, B.:Thrombocytopenia II. Drug-induced thrombocytopenia. Acta Med. Scand. 191:541～548, 1972.

6) Bolton, F. G. and Dameshek, W.:Thrombocytopenic purpura due to quinidine. I. Clinical studies. Blood 11:527～564, 1956.

7) Karpatkin, S.:Autoimmune thrombocytopenic purpura. Am. J. Med. Sci. 261:127～138, 1971.

8) Nieweg, H. O., Weenik-de Vries, J. Snijder, J. A. M. and Bouma, H. G. D.:The occurrence of antibodies against acetylsalicylic acid and related compounds in thrombocytopenic purpura. Brit. J. Haematol. 17:306, 1969.

9) Ackroyd, J. F.:Allergic purpura, including purpura due to foods, drugs and infections. Am. J. Med. 14:605～632, 1953.

10) Deykin, D., and Hellerstein, L. J.:The assessment of drug-dependent and isoimmune antiplatelet antibodies by the use of platelet aggregometry. J. Clin. Invest. 51:3142～3153, 1972.

11) Okuma, M.:Studies on experimental immune thrombocytopenia. IV. Thrombocytopenia in rabbits induced by sensitization with quinidine. Acta Haematol JPN 30:767～784, 1967.

12) Dausset, J.:The role of the "peri-platelet atmosphere"in the mechanism of thrombocytopenic purpura due to sedormid. in Sensitivity Reactions to Drugs (ed. Rosenheim, M. L. and Moulton, R.). p.63～76, Blackwell, Oxford, 1958.

13) Aster, R. H.:Detection of antiplatelet antibodies:Inhibition of clot retraction. in Hematology (ed. Williams, W. J., Beutler, E., Erslev, A. J. and Rundles, R. W.) p. 1660～1662, McGraw-Hill, New York, 1977.

14) Horowitz, H. L, Rappaport, H. I., Young, R. C. and Fujimoto, M. M.:Change in platelet factor 3 as a means of demonstrating immunereactions involving Platelets:Its use as a test for quinidine-induced thrombocytopenia. Transfusion 5:336～343, 1965.

15) 大熊稔:アレルギー性栓球減少性紫斑病, 第17回日本医学会総会学術講演集, IV, p. 827～835, 1967.

16) Shulman, N. R.:Immunoreactions involving platelets. IV. Studies on the pathogenesis of thrombocytopenia in drug purpura using test dosis of quinidine in sensitized individuals; their implications in idiopathic thrombocytopenic purpura. J. Exp. Med. 107:711～729, 1958.

17) Okuma, M.:Studies on experimental immune thrombocytopenia. V. Serological studies on thrombocytopenia in rabbits induced by quinidine with special reference to the role of quinidine in the lmmunological reactions. Acta Haematol. JPN 30:785～799, 1967.

18) Eisner, E. V. and Shahidi, N. T.:Immune thrombocytopenia due to a drug metabolite. New Engl. J. Med. 287:376～381, 1972.

19) Miescher, P. and Miescher, A.:Die Sedormid Anaphylaxie. Schweiz. 1952.
pubmed

20) Miescher, P. A. und Nydegger, U.:Arzneimittelbedingte Thrombozytopenie. Blut 32:329～336, 1976.

21) Gangarosa, E. J., Johnson, T. R. and Ramos, H. S.:Ristocetin-induced thrombocytopenia:Site and mechanism of action. Arch. Int. Med. 105:83～89, 1960.

22) England. J. M, and Smith, D.S.:Gold-induced thrombocytopenia and response to dimercaprol. Brit. Med. J. 2:748～749, 1972.

23) Belkin, G. A.,:Cockail purpura:An unusual case of quinine sensitivity. Ann. Int. Med. 66:583～586, 1967.

24) Vincent, P. C. and de Gruchy, G. C.:Complications and treatment of a plastic anemia. Brit. J. Haematol. 13:977～979, 1967.

25) Laboratory studies in drug-induced pancytopenia. Brit. Med. J. 280:429～430, 1980.

26) Yunis, A. A.:Chloramphenicol toxicity. in Blood Disorders due to Drugs and Other Agents. (ed. Girdwood, R. H.) p. 107～126, Excerpta Medica, Amsterdam, 1973.

27) O'Brien, J. R.:A comparison of an effect of different anti-inflammatory drugs on human platelets. J. Clin. Pathol. 23:522～525, 1970.

28) Doan, C. A., Bouroncle, B. A. and Wiseman, B.K.:Idiopathic and secondary thrombocytopenic purpura:Clinical study and evaluation of 381 cases over a period of 28 years. Ann. Int. Med. 53:861～876, 1960.

29) Mustard, J. F. and Packham, M. A.:Platelets, thrombosis and drugs. Drugs 9:19～76, 1975.

30) 大熊稔:プロスタグランディンとその周辺. 血液 (血小板), 現代医療 12: 895～907, 1980.

31) Cunningham, R. J., III, Brouhard, B.H., Travis, L.B., Berger, M. and Petrusick, T.:Hemorrhage as a complication of dipyridamole therapy. South. Med. J. 72:498～499, 1979.

32) Shattil, S. J., Bennett, J. S., McDonogh, M. and Turnbull, J.:Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface. J.Clin. Invest. 65:329-337, 1980. 266

3. 凝固亢進の臨床

P.266 掲載の参考文献

1) Selye, M.:Thrombohemorrhagic Phenomena. Thomas, Springfield, 1966.

2) Owen, C. A., Jr. & Bowie, E. J. W.:Chronic intravascular coagulation and fibrinolysis (ICF) syndromes (DIC). Sem, Thromb, Hemost. 3:268～290, 1977.

3) Schneider, C. L:"Fibrin embolism" (disseminated intravascular coagulation) with defibrination as one of the end results during placenta abruptio. Surg. Gyn. Obst., 92:27～34, 1951.

4) Colman, R. W. & Rodriguez-Erdmann, F.:Terminology of intravascular coagulation, New Eng, J. Med., 282:99, 1970.266

5) Lasch, H. G., Krecke, H.-J., Rodriguez-Erdmann, F., Sessner, H. H. & Schutterle, G.:Verbrauchskoagulopathien. Pathogenese und Therapie. Folia haemat. (N. F.) 6:325～330, 1961.

6) 松田保:いわゆる local DIC. 医学のあゆみ, 109:725～737, 1979.

7) Minna, J. D., Robboy, S. J. & Colman, R. W.:Disseninated Intravascular Coagulation in Man. Thomas, Springfield, 1974.

8) 松田保:DIC, 改訂版, 中外医学社, 東京, 1979.

9) Stetson, C. A. & Good, R. A.:Studies on the mechanism of the Shwartzman phenomenon:Evidence for the participation of polymorphon-nuclear leukocytes in the phenomenon. J. Sxp. Med., 93:49～63, 1951.

10) Komp, D. M. & Donaldson, M. H.:Sepsis in leukemia and the Shwartzman reaction, Amer. J. Dis. Child., 119:114～116, 1970.

11) Gaynor, E., Bouvier, C. A. & Spaet, T. H.:Circulating endothelial cells in endotoxin-treated rabbits. Clin. Res., 16:535 (abstract), 1968.

12) Muller-Berghaus, G.:Pathophysiology of generalized intravascular Coagulation. Sem. Thromb. Hemost., 3:209～246, 1977.

13) Cameron, J. S.:Bright's disease today:The pathgenesis and treatment of gromeluronephritis. Br. Med. J., 4:160～163, 1973.

14) DICとその周辺:医学のあゆみ, 109:701～980, 1979.

15) 青木延雄, 松田道雄, 吉田信彦, 坂田洋一:DIC の成因に関する調査結果. 汎発性血管内血液凝固症調査研究班, 昭和53年度業績報告, 81～95.

16) 前川正, 小林紀夫, 権守日出海, 竹内季雄, 上野達雄, 田中省三, 田中廣, 高田雅史:DIC の臨床病態統計, 全国患者数推定, ibid, 1～17.

17) Hardaway, R. M., III.:Syndromes of Disseminated Intravascular Coagulation. Thomas, Springfield, 1966.

18) Robboy, S. J., Colman, R. W. & Minna, J. D.:Pathology of disseminated intravascular coagulation (DIC). Human Path., 3:327～343, 1972.

19) 前川正, 鈴木芳郎, 伊藤琢夫:Consumption coagulopathy における凝血学的変化の成立機転について. 日血会誌, 34:suppl. 65～74, 1971.

20) McKay, D. G.:Coagulation. Academic Press, New York, 1973.

21) Deykin, D.:The clinical challenge of disseminated intravascular coagulation. New Eng. J. Med., 283:639～644, 1970.

22) Cooper, H. A., Bowie, E. J. W. & Owen, C. A., Jr.:Evaluation of patients with increased fibrinolytic split products (FSP) in their serum. Mayo Clin. Proc., 49:654～657, 1974.

23) Sharp, A. A.:Diagnosis and treatment of disseminated intravascular coagulation. Br. Med. Bull., 33:265～272, 1977.

24) Al-Mondhiry, H.:Disseminated intravascular coagulation:experience in a major cancer center. Thromb. Diath. Haemorrh., 34:181～193, 1975.

25) 小島瑞, 島村香也子, 金成拓二:DIC におけるフィブリン血栓の形態学的観察. 汎発性血管内血液凝固症調査研究班, 昭和53年度業績集報告, 54～75, 140～144.

26) 青木延雄, 吉田信彦, 坂田洋一, 松田道生, 山中恒夫:血漿アンチトロンビンIII濃縮分画によるDICの治療について. 汎発性血管内血液凝固症調査研究班, 昭和53年度業績集報告, 125～130.

27) Handley, A. J.:Heparin therapy; A simple test of control. J. Clin. Path., 27:250～252, 1974.

28) 松田保:DIC の治療. 汎発性血管内血液凝固症調査研究班, 昭和53年度業績集報告, 115～124.

29) Mant, M. J., Fisk, R. L & Amy, R. W. M.:Chronic disseminated intravascular coagulation due to occult carcinoma. Amer. J. Med. Sci., 274:69～74, 1977.

P.288 掲載の参考文献

1) Mustard, J. F., Perry, D. W., Kinlough-Rathbone, R. L et al:Factors responsible for ADP-induced release reaction of human platelets. Am. J. Physiol. 228:1757～1765, 1975.

2) Hamberg, M., Samuelsson, J. and Samuelsson, B.:Thromboxanes:A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Nat. Acad. Sci (USA) 72:2994～2998, 1975.

3) Hamberg, M., Svensson, J. and Samuelsson, B.:Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins. Proc. Nat. Acad. Sci.(USA) 71:3824～3828, 1974.

4) Hamberg, M. and Samuelsson, B.:Prostaglandin endoperoxides. Novel transformations of arachidon acid in human platelets. Proc. Nat. Acad. Sci. (USA) 71:3400～3404, 1974.

5) Vane, J. R.:Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231:232～237, 1971.

6) Moncada, S., Higgs, E. A. and Vane J. R.:Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibition of platelet aggregation. Lancet 1:18～20, 1977.

7) Rome, L H., Lands, W. E. M., Roth, G. J. et al.:Aspirin as an acetylating agent for prostaglandin synthesis. Prostaglandin 11:23～30, 1976.

8) Elkeles, R. S., Hampton, J. R., Honoon A. J. et al.:Effect of a pyrimidopyrimidine compound on platelet behavior in vitro and in vivo. Lancet 2:751～754, 1968.

9) Harker, L A. and Slichter, S. J.:Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N. Engl. J. Med. 283:1302～1305, 1970.

10) Weily, H. S. and Genton, E.:Altered platelet function in patients with prosthetic mitra valves:effects of sulfinpyrazone therapy. Circulation 49:967～972, 1970.

11) Sullivan, J. M. Harken, D, E. and Gorlin, R.:Pharmacologic control of thromboembolic complications of cardiac-valve replacement. A preliminary report. N. Engl. J. Med. 279:576～580, 1968.

12) Evan, G.:Effect of drugs that suppress platelet surface interaction on incidence of amaurosis fugax and transient cerebral ischemia. Surg. Forum 23:239～241, 1972.

13) Deykin, M. L., Kolar, D. J. and Jones, F. J.:Differences in the occurrence of carotid transient ischemic attacks associated with antiplatelet aggregation therapy. Stroke 4:732～736, 1973.

14) The Canadian Cooperative Group:A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N. Engl. J. Med. 299:53～59, 1978.

15) Elwood, P. C., Cochrane, A. L, Burr, M. L. et al.:A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infraction. Br. J. Med. 1:436～440, 1974.

16) Kinkaid. Smith, P.:Modification of the valvular lesions of rejection in cadaveric renal allografts by dipyridamole and anticoagulants. Lancet 2:920～922, 1969.

17) Abilgaard, U.:Heparin cofactor and antithrombin. Thromb. Diath. Hemorrh. (Stuttg) 33:38～42, 1974.

18) Rosenberg, R. D. and Damus, P. S.:The purification and mechanism of action of human antithrombin. heparin cofactor. J. Biol. Chem. 248:6490～6505, 1973.

19) 前川正:抗凝血薬療法. 村山元孝監修「血栓症-基礎と臨床-」, 日本メディカルセンター東京, p. 192, 1977.

20) Yin, E. T.:Theory and practice of minidose heparin in surgical patients. Circulation 47:671～676, 1974.

21) Wessler, S.:Mini-dose heparin. Thromb. Diath. Haemorrh. (Stuttg.) 34:718～726, 1975.

22) Kakkar, V. V., Corrigan, T., Spindler, J. et al.:Efficacy of low doses of heparin in the prevention of deep vein thrombosis after major surgery. A double. blind randomized trial. Lancet 2:101～106, 1972.

23) Thomas, D. P.:Heparin:chemistry and clinical usage. In Kakker, V. V. and Thomas, D. P ed., Academic Press, London, pp. 189～199, 1976

24) Salzman, E. W., Deykin, D., Shapirs, R. M. et al.:Management of heparin therapy:Controlled prospective trial. N. Engl. J. Med. 292:1046～1050, 1975.

25) Marciniak, E. and Gockerman, J. P.:Heparin-induced decrease in circulating antithrombin-III. Lancet 2:581～584, 1977.

26) Stenfio, J. and Suttie, J. W.:Vitamin K-dependent formation of rcarboxyglutamic acid. Ann. Rev. Biochem. 46:157～172, 1977.

27) Douglas, A. S. and McNicol G. P.:Anticoagulant therapy. In Human Blood Coagulation, Haemostasis and Thrombosis. Biggs, R. ed. Black-well Scientific Publications, Oxford, London, Edinburgh, Melbourne, p. 509, 1972.

28) Mackie, M. J. and Douglas, A. S.:Oral anticoagulants in arterial disease. Br. Med. Bull. 34:177～182, 1978.

29) 小川信久:ウロキナーゼ, 青木延雄, 岩永貞昭編「凝固・線溶・キニン」中外医学社, 東京, pp. 314～319, 1979.

30) Kakkar, V. V. and Scully, M. F.:Thrombolytic therapy. Br. Med. Bull. 34:191～199, 1979.

31) Aoki, N.:Natural inhibitors of fibrinolysis. Progr. Cardiovasc. Dis. 21:267～286, 1979.

32) Sakata, Y. and Aoki, N.:Cross-linking of α 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J. Clin. Invest., 65:290～297, 1980.

33) Sherry, S., Fletcher, A. P. and Alkjaersig, N.:Fibrinolysis and fibrinolytic activity in man, Physiol. Rev. 39:343～382, 1959.

34) 青木延雄:線溶療法, 臨牀と研究 53:1030～1033, 1976.
Medical*Online

35) A national cooperative study. The urokinase/pulmonary embolism trial. Circulation 47 (Suppl II), 1973.

36) A national cooperative study:Urokinase-streptokinase embolism trial. Phase 2 results. JAMA 229:1606～1613, 1974.

37) Aoki, N., Moroi, M., Matsuda, M. et al., The behavior of α 2-plasmin inhibitor in fibrinolytic states. J. Clin. Invest. 60:361～369, 1977.

38) Hayashi, S. and Yamada, K.:Role of α 2-plasmin inhibitor in the appearance of fibrinolytic activity during urokinase administration and an evaluation of the optimal urokinase dosage. Thromb. Res. 16:393～400, 1979.

39) 松田保:Urokinase 療法-理論と実際-, 内科 44:415～420, 1979.

40) Verstraete, M.:Biochemical and clinical aspects of thrombolysis. Seminars in Hematology 15:35～54, 1978.

41) Synthetic Fibrinolytic Thrombolytic Agents-Chemical, Biochemical, Pharmacological and Clinical Aspects. von Kaulla, K. N. and Davidson, J. F. ed. Charles C Thomas, Springfield, 1975.

4. 各科領域の出血・凝固異常

P.305 掲載の参考文献

1) 松田保:改訂版DIC, 中外医学社, 東京, 1979.

2) Jurgens, J.:Hamorrhagische Diathesen und Blutungen im Alter aus Klinischer Sicht. Thrombos. Diathes. Haemorrh. 41 (suppl.):225, 1970.

3) Eccles, J. T.:Control of warfarin therapy in the elderly. Age and Ageing 4:161, 1975.
pubmed

4) 松田保:心筋梗塞と血液凝固, 心臓10:231, 1978.

5) 松田保:脳血管障害における凝固, 脳と神経30:13, 1978.

6) Beneke, G.:Frequenz thromboembolischer Erkrankungen im Alter. Thrombos. Diathes. Haemorrh. 41 (suppl):9, 1970. 305

7) Korsan-Bengtsen, K., Bengtsson, C. and Tibblin, E.:Blood coagulation, fibrinolysis and platelet function in women aged 38, 46, 50, 54 and 60. Acta Med. Scand. 193:543, 1973.
pubmed

8) 前川正:老年者と臨床検査成績の評価, 血液凝固能-線溶能, 治療 58: 353, 1976.

9) Dodds, W. J., Moynihan, A. C., Benson, R. E., et al.:The value of age-and sex-matched controls for coagulation studies. Br. J. Haematol. 29:305, 1975.
pubmed

10) Jeremic, M., Weisert, O. and Gedde-Dahl, T. W.:Factor VIII (AHG) levels in 1016 regular blood donors. Scand. J. Clin. Lab. Invest. 36:461, 1976.

11) Brozovic, M., Stirling, Y., Harricks, C., et al.:Factor VII in an industrial population. Br. J. Haematol. 28:381, 1974.

12) 松田保:加齢と凝固線溶-凝血学的にみた老化と動脈硬化, 内科 34: 41, 1974.

13) Korsan-Bengtsen, K.:Risk factors in the pathogenesis of thrombosis. Thrombos. Diathes. Hemorrh. 51 (suppl.):199, 1972.

14) Hamilton, P. T., Dawson, A. A., Ogston, D., et al.:The effect of age on the fibrinolytic enzyme system. J. Clin. Pathol. 27:326, 1974.

15) Egbring, R. u. Kollewe, J.:Die Transglutaminase-Aktivitat (Faktor XIII) des thrombozytenarmen und-reichen Plasmas bei Patienten im hohen Lebensalter. Thrombos. Diathes. Haemorrh. 41 (suppl.):127, 1970.

16) Martin, M. u. Kokossulis, P.:Die Thrombozytenglasadhasivitat in Abhangigkeit von Lebensalter., Lipidstatus, Hamatokritwert und arterieller Verschlusskrankheit. Thrombos. Diathes. Haemorrh. 41 (suppl.):137, 1970.

17) Berkarda, B., Akokan, G. and Derman, U.:Fibrinolytic response to physical exercise in males. Atherosclerosis 13:85, 1971.
pubmed

18) Rasche, H. u. Hiemeyer, V.:Zur Hypofibrinolyse als Ursache der Altersthrombophilie. Thrombos. Diathes. Haemorrh. 41 (suppl):103, 1970.

19) 松田保, 小河原緑, 児玉直子ほか:老年者の凝固・線溶-加齢と凝固線溶阻止因子ならびにプラスミノゲン, 血液と脈管 9:35, 1978.

20) Fagerhol, M. K. and Abildgaard, U.:Immunological studies on human antithrombin III; influence of age, sex, and role of oral contraceptives on serum concentration. Scand. J. Haematol. 7:5, 1970.

21) 松田保, 小河原緑, 児玉直子ほか:加齢とアンチトロンビンIII, 医用酵素 2:47, 1976.

22) Currimbhoy, A., Vinciguerra, V., Palakavongs, P., et al.:Fletcher factor deficiency and myocardial infarction. Am. J. Clin. Pathol. 65:970, 1976.
pubmed

23) Ross, R. and Glomset, J.:The pathogenesis of atherosclerosis. N. Engl. J Med. 295:369 & 420, 1976.

24) Friedman, R. J., Stemerman, M. B, Wenz, B., et al.:The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits; smooth muscle cell proliferation and re-endothelialization. J. Clin. Invest. 60:1191, 1977.

25) Harker, L. A., Ross, R., Slichter, S. J, et al.:Homocystine-induced arteriosclerosis; the role of endothelial cell injury and platelet response in its genesis. J. Clin. Invest. 58:731, 1976.

26) Fuster, V., Bowie, W. E. J., Lewis, J. C., et al.:Resistance to arteriosclerosis in pigs with von Willebrand's disease; spontaneous and high cholesterol diet-induced arteriosclerosis. J. Clin. Invest. 61:722, 1978.

27) Dembinska-Kiec, A., Grygiewska, T., Zmuda, A., et al:The generation of prostacyclin by artries and by the coronary vascular bed is reduced in experimental atherosclerosis in rabbits. Prostaglandins 14:1025, 1977.

28) Villa, S., Mysliwiec, M. and deGaetano, G.:Prostacyclin and atherosclerosis in rats. Lancet 1:1216, 1977.

29) Moncada, S., Higgs, E. A. and Vane, J. R.:Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet 1:18, 1977.
pubmed

30) Dyerberg, J., Bang, H. O., Stoffersen, E., et al.:Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis. Lancet:2117, 1978.

P.333 掲載の参考文献

1) 真木正博:分子化学からみた血液凝固機転. Med. Postgraduates, 17:585, 1979.

2) 真木正博:分子化学からみた凝固, 線溶, キニン産生とその調節機構. Med. Postgraduates, 17:642, 1979.

3) Bode, W:Activation, action and inhibition of trypsinogen-trypsin. In:The physiological inhibitors of blood coagulation and fibrinolysis. (Eds. Collen, D., Wiman, B. and Verstraete, M.) p. 5, Elsevier, North Holland, Amsterdam, New York, Oxford, 1978.

4) 真木正博, 曽我賢次次:Possible role of Prekallikrein in the mechanism of labor. 厚生省・汎発性血管内血液凝固症調査研究班・昭和54年度業績集, p. 128, 1980.

5) 真木正博:妊娠・分娩・産褥と血栓症. 田中健茂編, 血栓症, p. 165, 文光堂, 1977.

6) 真木正博, 曽我賢次, 関晴夫:Fibrinolytic activity during pregnancy. 厚生省・汎発性血管内血液凝固症調査研究班・昭和54年度業績集, p. 132, 1980.

7) 寺尾俊彦, 他:先天性血液凝固異常と妊娠分娩. 産婦人科血液, 2 (2):13, 1978.

8) 真木正博:産科における ITP. クリニカ, 5:115, 1978.

9) 中村公一, 他:白血病と妊娠の合併. 臨床血液. 14:580, 1973.

10) 寺尾俊彦:血液疾患と妊娠分娩. 産婦治療, 32:305, 1976.

11) 中山志郎, 他:妊娠と再生不良性貧血. 臨床血液, 14:659, 1973.

12) 真木正博:産婦人科領域におけるDICの臨床-主として病理機転を中心に-, 日産婦関東連会報, 29:18, 1979.

13) 真木正博:産婦人科領域におけるDICの臨床-主として診断や治療を中心に-. 日産婦埼玉地方部会報, 8:107, 1979.

14) 真木正博:血管内凝固症候群. 金原出版, 1977.

15) 真木正博:DIC とスコアリング, 産婦治療, 47:298, 1983.

P.350 掲載の参考文献

1) 神前五郎, 田中健一:出血傾向と外科外科 34, 449-56, 1972.

2) 松田道生, 若林邦夫:外科における出血傾向外科 37, 700-5, 1975.

3) 林四郎, 石曽根新八, 清水公男, 清水幹男:出血を起し易い要因とそのチェツク臨床外科 34, 1203-10, 1979.

4) 大里敬一:術前患者の止血機構検査とその評価消化器外科 2, 651-5, 1979

5) 真木正博:止血の実際金原, 昭44.

6) 河合忠, 竹中道子:血液凝固医学書院 1978.

7) 前川正編:出血傾向のすべて南江堂昭52.

8) 上田, 武内, 豊倉編:出血素因南江堂昭54.

9) 高久史麿:止血剤消化器外科 2, 940-5, 1979.

10) 鳥居有人:輸血および血液製剤消化器外科 2, 951-8, 1979.

11) 福井弘:血友病南江堂昭52.

12) 長尾大:先天性出血素因と外科的処置外科 37, 776-82, 1975.

13) 安永幸二郎:特発性血小板減少性紫斑病 8) による.
Medical*Online

14) 岩永隆行, 雨宮洋一:血小板輸血の方法と効果臨床血液 18, 587-95, 1979.

15) 山中学:血液凝固異常に対する薬剤の作用機序外科 37, 788-94, 1975.

16) 永末道文, 小林迫夫, 井口潔:黄疸消化器外科 2, 665-72, 1979.

17) 黒田慧, 草間悟:肝・胆道疾患消化器外科 2, 753-66, 1979.

18) 福井博, 辻井正, 松山義則:肝・胆道疾患における DIC 臨床病理 26, 817-24, 1978.
Medical*Online

19) 大城孟, 村上文夫:凝固障害による出血傾向臨床外科 33, 542-50, 1978.

20) 長谷川博, 山崎普, 島村善行:肝切除後の輸液臨床成人病 8, 477-81, 1978.

21) 眞木正博:血管内血液凝固症候群外科 37, 783-7, 1975.

22) 松田保:血管内凝固症候群 (DIC) 臨床血液 17, 1139-52, 1976.

23) 今岡眞義:外科領域における DIC について臨床病理 26, 825-9, 1978.

24) 今岡眞義:重症感染とDIC 臨床科学 14, 1241-7, 1978.

25) 大里敬一, 武田成彰, 石臥達雄, 高木輝, 前田義章:血管内凝固症候群の治療成績とくにヘパリン治療について日外会誌 77, 1366-76, 昭51.

26) 眞木正博, 成田潤, 富崎安夫, 品川信良永山正剛:産科における急性DICの臨床臨床科学 14, 1956-62, 1978.

27) 大里敬一, 高木輝, 武田成彰:不適合輸血による血管内凝固 (DIC) の発生とヘパリン治療の意義日外会誌 78, 1062-8, 昭52.

28) 神前五郎, 今岡眞義:輸血に伴う生体反応-出血素因臨床外科 31, 595- 9, 1976.

29) Miller, R. D., T. O. Robbins, M. J. Tong, S. L. Barton:Coagulation defects associated with massive blood transfusions Ann. Surg. 174, 794-80, 1971.

30) Handin, R. I., Valeri, C. R.:Hemostatic effectiveness of platelets stored at 22℃ New Engl. J. Med. 285, 538-43, 1971.

31) Gomes, M. M, R., D. C. McGoon:Bleeding patterns after open heart surgery J. Thorac. Cardiov. Surg. 60, 87-97, 1970.

32) 松田光彦, 龍田憲和, 大頭信義, 山田公弥, 青嶋実, 日笠頼則:体外循環と賦活凝固時間試験 (ヘモクロンタイム) 人工臓器 6, 93-7, 1977.

33) Verska, J. J.:Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis Ann. Thorac. Surg. 24, 170-3, 1977.
pubmed

34) Babka, R., Cooley, C., El. Etr A., Pifarre R.:Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery J. Thorac. Cardiov. Surg. 73, 780-2, 1977.

35) Young, J. A., Kisker C. T., Doty D. B.:Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann. Thorac. Surg. 26, 231-41, 1978.
pubmed

36) 大里敬一, 加藤秀典:外科領域におけるDIC-特に体外循環, 重度外傷について-臨床科学 14, 1948-55, 1978.

37) 村井正元:Thromboelastograph による超低体温麻酔時の凝血機能に関する研究日胸外会誌 12, 1021-43, 1964.

38) 新津勝宏:外科領域への低温の応用産婦人科の世界 24, 17-23, 1972.

39) 新津勝宏, 安井豊, 村井正元, 西川孝戒, 牧田俊宣:低体温開心術と止血剤外科 30, 510-4, 昭43.

40) 前川正, 小林紀夫:癌とDIC 臨床科学 14, 1232-40, 1978.

41) 村田吉郎, 日浅義雄, 大島正人:病理解剖からみた DIC 臨床病理 26, 840-4, 1978.

42) 村上文夫:手術と線溶系日医会誌 70, 1179-89, 昭48.

43) 高田明和, 高田由美子:線溶と疾病臨床科学 14, 1224-31, 1978.

44) 村上文夫:出血傾向日外会誌 76, 395-8, 昭50.

45) 坂田洋一, 青木延雄:DICと線溶臨床科学 14, 1208-16, 1978

はじめての方へ

個人／法人会員登録のご案内